Prothena Co. plc (NASDAQ:PRTA) Shares Bought by Barclays PLC

Barclays PLC grew its position in shares of Prothena Co. plc (NASDAQ:PRTA) by 110.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,222 shares of the biotechnology company’s stock after purchasing an additional 49,916 shares during the period. Barclays PLC owned approximately 0.18% of Prothena worth $1,592,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Signaturefd LLC lifted its stake in Prothena by 182.1% during the second quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 863 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Prothena by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 4,026 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Prothena during the third quarter worth about $210,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Prothena by 13.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company’s stock worth $211,000 after buying an additional 1,186 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Prothena during the third quarter worth about $260,000. 97.08% of the stock is owned by institutional investors and hedge funds.

Prothena Stock Down 3.8 %

PRTA stock opened at $15.14 on Friday. Prothena Co. plc has a 52 week low of $11.70 and a 52 week high of $41.54. The company has a market cap of $814.67 million, a price-to-earnings ratio of -6.10 and a beta of 0.09. The business has a fifty day simple moving average of $15.56 and a 200-day simple moving average of $18.92.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.18) by $0.08. The company had revenue of $0.97 million during the quarter, compared to analyst estimates of $1.22 million. Prothena had a negative return on equity of 24.19% and a negative net margin of 98.86%. The firm’s revenue was down 98.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.38 earnings per share. As a group, analysts expect that Prothena Co. plc will post -2.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on PRTA shares. Bank of America cut their price target on shares of Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, December 19th. StockNews.com downgraded shares of Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research report on Monday, September 30th. HC Wainwright reiterated a “buy” rating and issued a $48.00 price target (down from $84.00) on shares of Prothena in a research report on Friday, December 20th. Finally, Chardan Capital assumed coverage on Prothena in a research report on Friday, December 20th. They issued a “buy” rating and a $40.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Prothena presently has an average rating of “Moderate Buy” and a consensus target price of $52.29.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.